Kornberger Petra, Skerra Arne
Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie; Technische Universität München; Freising-Weihenstephan, Germany.
MAbs. 2014 Mar-Apr;6(2):354-66. doi: 10.4161/mabs.27444. Epub 2013 Dec 9.
We report on the preparation of a new type of immunotoxin via in vitro ligation of the αHer2 antigen binding fragment (Fab) of the clinically-validated antibody trastuzumab to the plant toxin gelonin, employing catalysis by the bacterial enzyme sortase A (SrtA). The αHer2 Fab was fused with the extended SrtA recognition motif LPET↓GLEH 6 at the C-terminus of its heavy chain, thereby preventing interference with antigen binding, while the toxin was equipped with a Gly 2 sequence at its N-terminus, distant to the catalytically active site in the C-terminal region. Site-specific in vitro transpeptidation led to a novel antibody-toxin conjugate wherein gelonin had effectively replaced the Fc region of a conventional (monomerized) immunoglobulin. After optimization of reaction conditions and incubation time, the resulting Fab-Gelonin ligation product was purified to homogeneity in a two-step procedure by means of Strep-Tactin affinity chromatography--utilizing the Strep-tag II appended to gelonin--and size exclusion chromatography. Binding activity of the immunotoxin for the Her2 ectodomain was indistinguishable from the unligated Fab as measured by real-time surface plasmon resonance spectroscopy. Specific cytotoxic potency of Fab-Gelonin was demonstrated against two Her2-positive cell lines, resulting in EC 50 values of ~1 nM or lower, indicating a 1000-fold enhanced cell-killing activity compared with gelonin itself. Thus, our strategy provides a convenient route to the modular construction of functional immunotoxins from Fabs of established tumor-specific antibodies with gelonin or related proteotoxins, also avoiding the elevated biosafety levels that would be mandatory for the direct biotechnological preparation of corresponding fusion proteins.
我们报告了一种新型免疫毒素的制备方法,该方法是通过临床上已验证的抗体曲妥珠单抗的αHer2抗原结合片段(Fab)与植物毒素相思豆毒素,在细菌酶分选酶A(SrtA)的催化作用下进行体外连接。αHer2 Fab在其重链的C末端与扩展的SrtA识别基序LPET↓GLEH 6融合,从而防止对抗原结合的干扰,而毒素在其N末端配备了Gly 2序列,该序列与C末端区域的催化活性位点相距较远。位点特异性体外转肽作用产生了一种新型的抗体-毒素偶联物,其中相思豆毒素有效地取代了传统(单体化)免疫球蛋白的Fc区域。在优化反应条件和孵育时间后,通过两步法纯化得到的Fab-相思豆毒素连接产物,第一步利用附着在相思豆毒素上的链霉亲和素标签II进行链霉亲和素亲和层析,第二步进行尺寸排阻层析,使其达到均一性。通过实时表面等离子体共振光谱法测定,免疫毒素对Her2胞外域的结合活性与未连接的Fab没有区别。Fab-相思豆毒素对两种Her2阳性细胞系表现出特异性细胞毒性,其半数有效浓度(EC50)值约为1 nM或更低,表明与相思豆毒素本身相比,细胞杀伤活性提高了1000倍。因此,我们的策略为从已建立的肿瘤特异性抗体Fab与相思豆毒素或相关蛋白毒素构建功能性免疫毒素提供了一条便捷途径,同时也避免了直接生物技术制备相应融合蛋白所需的更高生物安全水平。